KALA BIO

KALA BIO is a dynamic clinical-stage biopharmaceutical company dedicated to pioneering research and development of innovative therapies for rare and severe eye diseases. At KALA BIO, a deep commitment to advancing the treatment of eye diseases drives the company's mission, reflected in its biologics-based investigational therapies that harness KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform.

KALA BIO's lead product candidate, KPI-012, a human MSC-S containing numerous human-derived biofactors, is currently in clinical development for treating persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. With Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, KPI-012 holds immense promise. KALA BIO is also exploring KPI-012's potential for treating Limbal Stem Cell Deficiency and other rare corneal diseases, alongside preclinical studies evaluating its MSC-S platform for retinal degenerative diseases. KALA BIO's primary address is 1167 Massachusetts Ave, Arlington, Massachusetts 02476, US, with an additional location at 1440 O'Brien Dr., Ste D, Menlo Park, CA 94025, US.

With a focus on innovation and patient well-being, KALA BIO is set to redefine the landscape of ocular therapeutics. For more detailed information about KALA BIO and its groundbreaking work, management will soon complete the company's profile. We invite the manager of KALA BIO to create a customized and exclusive company showcase and product listing on our platform to further highlight your achievements and attract new opportunities.